[go: up one dir, main page]

US20020094957A1 - Peptide binding the KLVFF-sequence of amyloid-beta - Google Patents

Peptide binding the KLVFF-sequence of amyloid-beta Download PDF

Info

Publication number
US20020094957A1
US20020094957A1 US09/850,061 US85006101A US2002094957A1 US 20020094957 A1 US20020094957 A1 US 20020094957A1 US 85006101 A US85006101 A US 85006101A US 2002094957 A1 US2002094957 A1 US 2002094957A1
Authority
US
United States
Prior art keywords
amino acid
bonded
amyloid
compound according
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/850,061
Inventor
Christer Nordstedt
Jan Naslund
Johan Thyberg
Lars Tjernberg
Lars Terenius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bellus Health International Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9504467A external-priority patent/SE9504467D0/en
Application filed by Individual filed Critical Individual
Priority to US09/850,061 priority Critical patent/US20020094957A1/en
Publication of US20020094957A1 publication Critical patent/US20020094957A1/en
Priority to US10/721,774 priority patent/US7288523B2/en
Assigned to NEUROCHEM (INTERNATIONAL) LIMITED reassignment NEUROCHEM (INTERNATIONAL) LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KAROLINSKA INNOVATIONS AB
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Definitions

  • the present invention relates to compounds, which are of special interest by their ability to bind to the KLVFF-sequence in the peptide amyloid ⁇ and to inhibit polymerization of the amyloid ⁇ peptide.
  • the compounds according to the invention are e.g. useful as medicaments and as tools for identification of substances to be used in the treatment or prevention of amyloidosis.
  • Amyloidosis is a condition which is characterized by the deposition of amyloid in organs or tissues of the human or animal body, either as a primary disease of unknown cause or secondary to chronic disease, such as tuberculosis or osteomyelitis.
  • AD Alzheimer's disease
  • the pre-eminent neuropathological feature of Alzheimer's disease (AD) is the deposition of amyloid in the brain parenchyma and cerebrovasculature (D. J. Selkoe, Neuron 6, 487-498 (1991); D. J. Selkoe, Annu. Rev. Cell Biol. 10, 373-403 (1994)).
  • amyloid ⁇ The basic component of such amyloid is a peptide termed amyloid ⁇ , or A ⁇ (G. C. Glenner, C. W. Wong, Biochem. Biophys. Res. Commun. 120, 885-890 (1984)). It is a 40 to 42 amino acids long proteolytic fragment of the Alzheimer amyloid precursor protein (APP), a protein expressed in most tissues (J. Kang, et al., Nature 325, 733-736 (1987)). Genetic and neuropathological studies provide strong evidence for a central role of A ⁇ in the pathogenesis of AD, but the pathophysiological consequences of the amyloid deposition are still unclear.
  • APP Alzheimer amyloid precursor protein
  • a ⁇ polymers and amyloid are toxic to neurons, either directly or indirectly, and hence cause neurodegeneration (C. Behl, J. B. Davis, R. Lesley, D. Schubert, Cell 77, 817-827 (1994); D. T. Loo, et al., ibid 90, 7951-7955 (1995)).
  • amyloid associated with Alzheimer's disease consists of thin fibrils of polymerized A ⁇ .
  • a rational pharmacological approach for the prevention of amyloidogenesis would therefore be to use drugs that specifically interfere with A ⁇ -A ⁇ interaction and polymerization.
  • Previous studies showed that A ⁇ polymerization in vivo and in vitro is a highly specific process, which probably involves an interaction between binding sequences in the A ⁇ peptide (J. Näslund, et al., Proc. Natl. Acad. Sci. USA 91, 8378-8382 (1994); J. Näslund, et al., Biochem. Biophys. Res. Commun. 204, 780-787 (1994)).
  • Wood et al (S. J. Wood, R. Wetzel, J. D. Martin, M. R. Hurle, Biochemistry 34, 724-730 (1995)) suggest that amino acid residues within or close to A ⁇ -16-20 are important for the adoption of the correct ⁇ -pleated sheet structure of A ⁇ and show that amino acids 17-23 in the amyloid ⁇ peptide (A ⁇ ) are essential for fibril formation and probably make up the ⁇ -sheet core of the fibrils.
  • Wood et al. have investigated the ability of their peptides to form amyloid fibrils in a solution containing solely the mutated or the wild-type peptide. However, no method or principle which makes it possible to inhibit A ⁇ of wild type from forming amyloid fibrils is devised and no use of the peptides as medicaments is suggested.
  • WO 95/08999 relates to amelioration of amnesia in Alzheimer's disease caused by deposition of amyloid ⁇ protein.
  • Three peptides are disclosed, which overcome the amnestic effects of ⁇ -12-28, a peptide homologous to A ⁇ .
  • WO 95/08999 describes the screening of several other peptides, which were neither significantly amnestic nor memory enhancing, of which one is KLVFF, SEQ. NO. 15 of the sequence listing therein.
  • EP 0 584 452 novel amyloid precursor proteins and the sequences thereof are disclosed. Peptide sequences that comprise KLVFF are revealed. However, neither binding to amyloid ⁇ peptide nor any inhibition of the polymerization thereof is suggested.
  • amyloid ⁇ peptide (A ⁇ ) into amyloid fibrils is a critical step in the pathogenesis of Alzheimer's disease.
  • a ⁇ molecules interact with a high degree of specificity during polymerization and fibril formation. It was assumed that ligands which bind to recognition sequences would be capable of inhibiting A ⁇ polymerization and possibly also dissolve pre-formed A ⁇ polymers in situ. The strategy in finding such A ⁇ ligands was to identify critical binding regions in A ⁇ and, based on their sequences, develop a compound capable of blocking the A ⁇ -A ⁇ binding.
  • Lys-Leu-Val-Phe-Phe (KLVFF) sequence in A ⁇ is necessary for polymerization to occur.
  • Peptides incorporating this sequence bind to A ⁇ and are capable of blocking the fibril formation of A ⁇ -1-40 and are therefore potentially useful as drugs.
  • Lys-Leu-Val-Phe-Phe (16-20) motif serves as a structural basis for the development of peptide and non-peptide agents aimed at inhibiting amyloidogenesis in vivo. This is a novel finding and the compounds are of utmost interest as being useful as drugs for Alzheimer's disease.
  • the present invention relates to compounds which are able to bind to the Lys-Leu-Val-Phe-Phe-sequence, or KLVFF-sequence, in the peptide amyloid ⁇ . More specifically, the compounds according to the invention are defined by their formula (I):
  • X′ means any group or amino acid imparting to the compound of formula (I) the ability to bind to the KLVFF-sequence in amyloid ⁇ peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline;
  • Y′ means any amino acid
  • Z′ means any non-acidic amino acid:
  • A′ means a direct bond or an ⁇ -amino acid bonded at the carboxyl terminal of the ⁇ -carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the ⁇ -carboxy group;
  • B′ means a direct bond or an ⁇ -amino acid bonded at the ⁇ -nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the ⁇ -nitrogen of the N-terminal ⁇ -amino acid;
  • R 1 is H or —CO—R 3 bonded at the ⁇ -amino group of A′;
  • R 2 is H, —OR 4 or NR 5 R 6 , all bonded to the ⁇ -carboxyl group of the ⁇ -carboxyterminal of B′;
  • R 3 is a straight or branched carbon chain of 1-4 carbon atoms
  • R 4 is a straight or branched carbon chain of 1-4 carbon atoms
  • R 5 and R 6 independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are —(CH 2 ) n —, where n is 4-5;
  • R 1 and R 2 together can form a hydrocarbon ring or heterocyclic ring
  • all the ⁇ -amino acids can be either D- or L-isomers
  • alkyl is preferably meant a chain of 4 or less carbon atoms, e.g. methyl, ethyl, propyl or butyl.
  • cykloalkyl is preferably meant a ring of 3, 4, 5 or 6 carbon atoms.
  • Aryl preferably means a phenyl group, which can be substituted, preferably by a methyl, ethyl, propyl or butyl group, an amino or a methoxy, ethoxy, propoxy or butoxy group.
  • the compound exhibits an ability to inhibit polymerization of amyloid ⁇ peptide.
  • all the amino acids of the compound are D-isomers.
  • Y′ is Lys
  • Z′ is Phe
  • R 1 -A′ NH—CH[—(CH 2 ) 4 —NH 2 ]—CO—Leu-X′—NH—CH[—CH 2 —Ph]—CO—B′-R 2 .
  • Y′ is Phe.
  • R 1 is acetyl
  • R 1 is H.
  • R 2 is H.
  • R 1 and R 2 are both H.
  • a second aspect of the present invention is the use of a compound of formula:
  • X′ means any group or amino acid imparting to the compound of formula (II) the ability to bind to the KLVFF-sequence in amyloid ⁇ peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline;
  • Y′ means any amino acid
  • Z′ means any non-acidic amino acid
  • A′ means a direct bond or an ⁇ -amino acid bonded at the carboxyl terminal of the ⁇ -carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the ⁇ -carboxy group;
  • B′ means a direct bond or an ⁇ -amino acid bonded at the ⁇ -nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the ⁇ -nitrogen of the N-terminal ⁇ -amino acid;
  • R 1 is H or —CO—R 3 bonded at the ⁇ -amino group of A′;
  • R 2 is H, —OR 4 or NR 5 R 6 , all bonded to the ⁇ -carboxylgroup of the ⁇ -carboxyterminal of B′;
  • R 3 is a straight or branched carbon chain of 1-4 carbon atoms
  • R 4 is a straight or branched carbon chain of 1-4 carbon atoms
  • R 5 and R 6 independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are —(CH 2 ) n — where n is 4-5;
  • R 1 and R 2 can together form a hydrocarbon ring or heterocyclic ring
  • all the ⁇ -amino acids can be either D- or L-isomers
  • alkyl is preferably meant a chain of 4 or less carbon atoms, e.g. methyl, ethyl, propyl or butyl.
  • cykloalkyl is preferably meant a ring of 3, 4, 5 or 6 carbon atoms.
  • Aryl preferably means a phenyl group, which can be substituted, preferably by a methyl, ethyl, propyl or butyl group, an amino or a methoxy, ethoxy, propoxy or butoxy group.
  • a compound is used, wherein all the amino acids are D-isomers.
  • Y′ is Lys.
  • Z′ is Phe, resulting in a compound of the following formula:
  • R 1 -A′ NH—CH[(CH 2 ) 4 —NH 2 ]—CO—Leu-X′—NH—CH[—CH 2 —Ph]—CO—B′R 2 .
  • a compound is used, wherein Y′ is Phe while Z′ is any non-acidic amino acid.
  • R 1 is acetyl.
  • R 1 and/or R 2 are H.
  • Yet another aspect of the present invention is a compound according to the invention for use as a medicament.
  • a compound preferably of the formula (I) or (II), which is able to bind to the KLVFF-sequence in amyloid ⁇ peptide and which has the ability to inhibit polymerization of amyloid ⁇ peptide, for the manufacture of a medicament for the treatment or prevention of amyloidosis, especially in the treatment or prevention of Alzheimer's disease associated with amyloidosis, for the treatment or prevention of demens in patients with Down's syndrome, for the treatment or prevention of Hereditary cerebral hemorrhage with amyloidosis (Dutch type) or for the prevention of fibril formation of human amyloid protein.
  • a last aspect of the present invention is a composition comprising a compound according to formula II and optionally a ligand capable of binding or interacting with the compound according to formula II and a carrier.
  • Said composition can e.g. be adapted for injection in a liquid carrier or for oral administration in a tablet or capsule.
  • K is lysine (Lys), L is leucine (Leu), V is valine (Val), F is phenylalanine (Phe), A is alanine (Ala) and E is glutamic acid (Glu).
  • any group giving the compound according to formula (I) the ability to bind to the KLVFF-sequence in the amyloid ⁇ peptide means that this group gives the compound a structure, which can fulfil the requirements given in claim 1 .
  • the hydrocarbon ring or heterocyclic ring has preferably 4-6 atoms, preferably C, N and S.
  • FIGS. 1 A and B A ⁇ -amyloid polymerization.
  • FIG. 2A Ten-mers corresponding to consecutive sequences of A ⁇ -1-40. Radioactivity bound to the filter was detected by autoradiography and quantified by densitometry.
  • FIG. 2B EVHHQKLVFF and N and C-terminal truncated fragments were synthesized and analyzed for affinity to 125 I-labelled A ⁇ -1-40.
  • FIG. 2C Each amino acid residue in KLVFF was systematically replaced with Ala and analyzed for affinity to 125 I-labelled A ⁇ -1-40.
  • FIG. 2D Sensorgram from surface plasmon resonance spectroscopy (BIAcore 2000).
  • FIGS. 3 A and B Content of non-aggregated peptide in the supernatants from incubations of wild-type and Ala-substituted A ⁇ -1-28 as analyzed by HPLC.
  • Peptide no. 1 corresponds to amino acids 1-10, peptide no. 2 to amino acids 2-11 etc.
  • the filter-bound peptides were incubated with radioactive A ⁇ -1-40. Following washing of the filter in high-salt buffer, bound radioactivity was estimated by autoradiography and densitometry. Following blocking with 0.05% Tween-20 in Tris-buffered saline (TBS), the filter was incubated in the presence of 20 ⁇ M 125 I-labelled A ⁇ -1-40 at 20° C. for 12 h in TBS, pH 7.3, supplemented with 1% bovine serum albumin. The filter was then washed repeatedly in the same buffer containing 0.5 M NaCl and dried. Radioactivity bound to the filter was visualized by autoradiography and quantitated using a densitometer.
  • TBS Tris-buffered saline
  • a) The measured binding should be interpreted as semiquantative, since the coupling efficiency and therefore the amount of peptide per spot may vary.
  • a region located in the central part of A ⁇ displayed prominent binding of radioactive A ⁇ -1-40.
  • Another binding region was the hydrophobic C-terminus of the molecule (D. Burdick, et al, J. Biol. Chem. 267, 546-554 (1992)) but binding here was considerably weaker (FIG. 2A).
  • peptide no. 11 (corresponding to A ⁇ -11-20) was selected for further studies.
  • AA served as linker between the active peptide and the chip (upper trace) and cysteine alone, indicating non-specific binding, (C) as control (lower trace). Arrows indicate start and stop of injection (FIG. 2D).
  • a ⁇ -1-28 (FIG. 3 A) and A ⁇ -1-28 AAVFA (FIG. 3 B) were incubated at 200 ⁇ M in TBS for 24 h at 37° C. in a shaking water bath. After incubation, the tubes were centrifuged at 20,000 g for 20 min and the content of non-aggregated peptide in the supernatants (FIG. 3 A, B) was analyzed using an established C4 RPLC system (12) whereas the aggregated peptides in the pellets were analyzed by electron microscopy after adsorption to formvar-coated grids and negative staining with 2% uranyl acetate in water.
  • a ⁇ -1-40 was incubated at 100 ⁇ M in TBS for 48 h at 37° C. in a shaking water bath, either alone or together with 100 ⁇ M AcKLVFFNH 2 .
  • the polymerized material was adsorbed to formvar-coated grids and negatively stained with 2% uranyl acetate in water.
  • the peptides were synthesized essentially as described by Frank (Frank R, 1992, Tetrahedron 42:9217-9232). Briefly, a spacer corresponding to 2 molecules of ⁇ -alanine was coupled to cellulose membranes (Whatman XX). The peptides were synthesized on these derivatized membranes using Fmoc protected and pentafluorophenyl-activated amino acids (AMS biotechnology) dissolved in N-methylpyrrolidone. Coupling efficiency was monitored using bromphenol blue.
  • the KLXXF motif in the A ⁇ molecule is not only critical for polymerization and fibril formation. During non-amyloidogenic processing of APP, the molecule is cleaved between amino acid residues K 16 and L 17 (F. S. Esch, et al., Science 248, 1122-1124 (1990)), leading to the formation of a fragment of A ⁇ termed p3 and corresponding to A ⁇ -17-40 or A ⁇ -17-42 (C. H ⁇ dot over (a) ⁇ ass, A. Y. Hung, M. G. Schlossmacher, D. B. Teplow, D. J. Selkoe, J. Biol. Chem. 268, 3021-3024 (1993)).
  • KLVFF binds stereo specifically to the homologous sequence in A ⁇ (i.e. . A ⁇ -16-20).
  • a ⁇ i.e. . A ⁇ -16-20.
  • KLVFF binds stereo specifically to the homologous sequence in A ⁇ (i.e. . A ⁇ -16-20).
  • KLVFF KLVFF
  • the risk of identifying D-pentapeptides that interact with nonrelevant regions in A ⁇ was eliminated.
  • the D-amino acid ligands were found not only to bind to A ⁇ but also to inhibit amyloid fibril formation. Since peptides built up of D-amino acids are resistant to proteolytic degradation, these ligands way be beneficial for inhibition of amyloidogenesis in vivo.
  • KLVFF will be useful in the identification of small organic molecules (e.g. by screening of substance libraries) with the ability to bind to A ⁇ in this relevant region and inhibit amyloid fibril formation (candidate drugs for the treatment of Alzheimer disease and other related amyloidoses).
  • Cyclodextrins have primarily been used to increase the solubility of a wide range of lipophilic drugs and it is unlikely that they would display any specificity for A ⁇ in vivo.
  • Congo red which is used in histochemistry to detect amyloid, binds to a wide array of non-A ⁇ amyloids as well as to other proteins with a high content of ⁇ -pleated sheet structures (W. G. Turnell, J. T. Finch, J. Mol. Biol. 227, 1205-1223 (1992)).
  • KLVFF amyloid fibril formation
  • the KLVFF peptide may serve as a model substance for the synthesis of non-peptide A ⁇ -ligands that interfere with the polymerization of A ⁇ molecules.
  • this region harbors at least one binding sequence required for the polymerization of A ⁇ into amyloid fibrils. It was also demonstrated that short peptides incorporating A ⁇ -16-20 can function as ligands that bind to A ⁇ and inhibit the formation of amyloid fibrils. Since these peptide ligands are relatively small, they are amenable for identification of other organic molecules with similar functional properties. Non-peptide homologues of KLVFF should be useful as pharmacological drugs for the treatment of Alzheimer's disease in the future.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to compounds of formula (I) or (II), which are of interest especially for inhibition of polymerization of amyloid β peptide, as model substances for synthesis of amyloid β peptide-ligands, as tools for the identification of other organic compounds with similar functional properties and/or as ligands for detection of amyloid deposits using e.g., positron emission tomography (PET). Formula (II) is: R1-A′-Y′-Leu-X′-Z′-B′-R2 in which X′ means any group or amino acid imparting to the compound according to formula (I) the ability to bind to the KLVFF-sequence in amyloid β peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline; Y′ means any amino acid; Z′ means any non-acidic amino acid; A′ means a direct bond or an α-amino acid bonded at the carboxyl terminal of the α-carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α-carboxy group; B′ means a direct bond or an α-amino acid bonded at the α-nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α-nitrogen of the N-terminal α-amino acid; R1 is H or —CO—R3 bonded at the α-amino group of A′; R2 is H, —OR4 or NR5R6, all bonded to the α-carboxyl group of the α-carboxyterminal of B′; R3 and R4 are straight or branched carbon chain of 1-4 carbon atoms; R5 and R6 are independently H, alkyl, cycloalkyl, aryl or substituted aryl or together are —(CH2)n— where n is 4-5; and R1 and R2 together can form a hydrocarbon ring or heterocyclic ring; all α-amino acids being either D- or L-isomers.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This is a continuation of International Application No. PCT/SE96/01621, filed Dec. 9, 1996, that designates the United States and which claims priority from Swedish Application No. 9504467-3, filed Dec. 12, 1995, and U.S. Provisional Application No. 60/009,386, filed Dec. 29, 1995, which are herein incorporated by reference. [0001]
    • INTRODUCTION
  • The present invention relates to compounds, which are of special interest by their ability to bind to the KLVFF-sequence in the peptide amyloid β and to inhibit polymerization of the amyloid β peptide. The compounds according to the invention are e.g. useful as medicaments and as tools for identification of substances to be used in the treatment or prevention of amyloidosis. [0002]
    • BACKGROUND OF THE INVENTION
  • Amyloidosis is a condition which is characterized by the deposition of amyloid in organs or tissues of the human or animal body, either as a primary disease of unknown cause or secondary to chronic disease, such as tuberculosis or osteomyelitis. In addition, it has also been found that the pre-eminent neuropathological feature of Alzheimer's disease (AD), a chronic condition of brain atrophy, is the deposition of amyloid in the brain parenchyma and cerebrovasculature (D. J. Selkoe, [0003] Neuron 6, 487-498 (1991); D. J. Selkoe, Annu. Rev. Cell Biol. 10, 373-403 (1994)).
  • The basic component of such amyloid is a peptide termed amyloid β, or Aβ (G. C. Glenner, C. W. Wong, [0004] Biochem. Biophys. Res. Commun. 120, 885-890 (1984)). It is a 40 to 42 amino acids long proteolytic fragment of the Alzheimer amyloid precursor protein (APP), a protein expressed in most tissues (J. Kang, et al., Nature 325, 733-736 (1987)). Genetic and neuropathological studies provide strong evidence for a central role of Aβ in the pathogenesis of AD, but the pathophysiological consequences of the amyloid deposition are still unclear. However, it has been suggested that Aβ polymers and amyloid are toxic to neurons, either directly or indirectly, and hence cause neurodegeneration (C. Behl, J. B. Davis, R. Lesley, D. Schubert, Cell 77, 817-827 (1994); D. T. Loo, et al., ibid 90, 7951-7955 (1995)).
  • The amyloid associated with Alzheimer's disease (AD) consists of thin fibrils of polymerized Aβ. A rational pharmacological approach for the prevention of amyloidogenesis would therefore be to use drugs that specifically interfere with Aβ-Aβ interaction and polymerization. Previous studies showed that Aβ polymerization in vivo and in vitro is a highly specific process, which probably involves an interaction between binding sequences in the Aβ peptide (J. Näslund, et al., [0005] Proc. Natl. Acad. Sci. USA 91, 8378-8382 (1994); J. Näslund, et al., Biochem. Biophys. Res. Commun. 204, 780-787 (1994)).
  • Wood et al (S. J. Wood, R. Wetzel, J. D. Martin, M. R. Hurle, [0006] Biochemistry 34, 724-730 (1995)) suggest that amino acid residues within or close to Aβ-16-20 are important for the adoption of the correct β-pleated sheet structure of Aβ and show that amino acids 17-23 in the amyloid β peptide (Aβ) are essential for fibril formation and probably make up the β-sheet core of the fibrils. In addition, Wood et al. have investigated the ability of their peptides to form amyloid fibrils in a solution containing solely the mutated or the wild-type peptide. However, no method or principle which makes it possible to inhibit Aβ of wild type from forming amyloid fibrils is devised and no use of the peptides as medicaments is suggested.
  • WO 95/08999 relates to amelioration of amnesia in Alzheimer's disease caused by deposition of amyloid β protein. Three peptides are disclosed, which overcome the amnestic effects of β-12-28, a peptide homologous to Aβ. In addition, WO 95/08999 describes the screening of several other peptides, which were neither significantly amnestic nor memory enhancing, of which one is KLVFF, SEQ. NO. 15 of the sequence listing therein. [0007]
  • In [0008] EP 0 584 452, novel amyloid precursor proteins and the sequences thereof are disclosed. Peptide sequences that comprise KLVFF are revealed. However, neither binding to amyloid β peptide nor any inhibition of the polymerization thereof is suggested.
    • SUMMARY OF THE INVENTION
  • Thus, the polymerization of the amyloid β peptide (Aβ) into amyloid fibrils is a critical step in the pathogenesis of Alzheimer's disease. [0009]
  • In vitro and in vivo studies of Aβ have shown that the Aβ molecules interact with a high degree of specificity during polymerization and fibril formation. It was assumed that ligands which bind to recognition sequences would be capable of inhibiting Aβ polymerization and possibly also dissolve pre-formed Aβ polymers in situ. The strategy in finding such Aβ ligands was to identify critical binding regions in Aβ and, based on their sequences, develop a compound capable of blocking the Aβ-Aβ binding. [0010]
  • According to the invention, it was hypothesized that compounds capable of binding to regions in the Aβ-molecule critical for its polymerization might inhibit amyloid fibril formation, as described in more detail below. [0011]
  • According to the invention, it has now been found that the Lys-Leu-Val-Phe-Phe (KLVFF) sequence in Aβ is necessary for polymerization to occur. Peptides incorporating this sequence bind to Aβ and are capable of blocking the fibril formation of Aβ-1-40 and are therefore potentially useful as drugs. [0012]
  • In addition, compounds have been found, which 1) are capable of binding to full-length Aβ, 2) are capable of blocking Aβ fibril formation and 3) do not form fibrils by themselves. [0013]
  • In addition, it has also been found that alanine-substituted Aβ-1-28 (Ala at position 16, 17, 20), in contrast to wild-type Aβ-1-28, does not form fibrils. [0014]
  • Thus, it was concluded that the Lys-Leu-Val-Phe-Phe (16-20) motif serves as a structural basis for the development of peptide and non-peptide agents aimed at inhibiting amyloidogenesis in vivo. This is a novel finding and the compounds are of utmost interest as being useful as drugs for Alzheimer's disease. [0015]
  • Further, the findings according to the invention are even more surprising on the basis of what was concluded from WO 95/08999 mentioned above. In WO 95/08999, it was concluded that KLVFF is not a potential candidate for the development of substances that can antagonize binding of Aβ and thus attenuate symptoms and progression of AD. Even though the teaching of said WO publication indicates the opposite, according to the present invention, it has now been found that KLVFF on the contrary is most useful for the development of new compounds defined by Formula (I) and (II) below. [0016]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to compounds which are able to bind to the Lys-Leu-Val-Phe-Phe-sequence, or KLVFF-sequence, in the peptide amyloid β. More specifically, the compounds according to the invention are defined by their formula (I): [0017]
  • R1-A′-Y′-Leu-X′-Z′-B′-R2   (I)
  • in which [0018]
  • X′ means any group or amino acid imparting to the compound of formula (I) the ability to bind to the KLVFF-sequence in amyloid β peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline; [0019]
  • Y′ means any amino acid; [0020]
  • Z′ means any non-acidic amino acid: [0021]
  • A′ means a direct bond or an α-amino acid bonded at the carboxyl terminal of the α-carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α-carboxy group; [0022]
  • B′ means a direct bond or an α-amino acid bonded at the α-nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α-nitrogen of the N-terminal α-amino acid; [0023]
  • R[0024] 1 is H or —CO—R3 bonded at the α-amino group of A′;
  • R[0025] 2 is H, —OR4 or NR5R6, all bonded to the α-carboxyl group of the α-carboxyterminal of B′;
  • R[0026] 3 is a straight or branched carbon chain of 1-4 carbon atoms;
  • R[0027] 4 is a straight or branched carbon chain of 1-4 carbon atoms;
  • R[0028] 5 and R6 independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are —(CH2)n—, where n is 4-5;
  • R[0029] 1 and R2 together can form a hydrocarbon ring or heterocyclic ring; and
  • all the α-amino acids can be either D- or L-isomers; [0030]
  • with the proviso that (I) is not Lys-Leu-Val-Phe-Phe. [0031]
  • With alkyl is preferably meant a chain of 4 or less carbon atoms, e.g. methyl, ethyl, propyl or butyl. [0032]
  • With cykloalkyl is preferably meant a ring of 3, 4, 5 or 6 carbon atoms. [0033]
  • Aryl preferably means a phenyl group, which can be substituted, preferably by a methyl, ethyl, propyl or butyl group, an amino or a methoxy, ethoxy, propoxy or butoxy group. [0034]
  • In a preferred embodiment of the present invention, the compound exhibits an ability to inhibit polymerization of amyloid β peptide. [0035]
  • In one embodiment of the invention, all the amino acids of the compound are D-isomers. [0036]
  • In one embodiment of the invention, Y′ is Lys, and in a particular embodiment of the invention, Z′ is Phe, resulting in a compound of the following formula: [0037]
  • R1-A′—NH—CH[—(CH2)4—NH2]—CO—Leu-X′—NH—CH[—CH2—Ph]—CO—B′-R2.
  • In an alternative embodiment of the invention, Y′ is Phe. [0038]
  • Preferred are compounds, wherein X′ is Val-Val. [0039]
  • In one embodiment of the present aspect of the invention, R[0040] 1 is acetyl.
  • In an alternative embodiment of the invention, R[0041] 1 is H. According to another embodiment, R2 is H. Alternatively, R1 and R2 are both H.
  • A second aspect of the present invention is the use of a compound of formula: [0042]
  • R1A′-Y′-Leu-X′-Z′-B′-R2   (II)
  • in which [0043]
  • X′ means any group or amino acid imparting to the compound of formula (II) the ability to bind to the KLVFF-sequence in amyloid β peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline; [0044]
  • Y′ means any amino acid; [0045]
  • Z′ means any non-acidic amino acid; [0046]
  • A′ means a direct bond or an α-amino acid bonded at the carboxyl terminal of the α-carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α-carboxy group; [0047]
  • B′ means a direct bond or an α-amino acid bonded at the α-nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α-nitrogen of the N-terminal α-amino acid; [0048]
  • R[0049] 1 is H or —CO—R3 bonded at the α-amino group of A′;
  • R[0050] 2 is H, —OR4 or NR5R6, all bonded to the α-carboxylgroup of the α-carboxyterminal of B′;
  • R[0051] 3 is a straight or branched carbon chain of 1-4 carbon atoms;
  • R[0052] 4 is a straight or branched carbon chain of 1-4 carbon atoms;
  • R[0053] 5 and R6 independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are —(CH2)n— where n is 4-5;
  • R[0054] 1 and R2 can together form a hydrocarbon ring or heterocyclic ring; and
  • all the α-amino acids can be either D- or L-isomers; [0055]
  • for inhibition of polymerization of amyloid β peptide, as a model substance for synthesis of amyloid β peptide-ligands for inhibition of polymerization of amyloid β peptide, as a tool for the identification of other organic compounds with similar functional properties or as ligand for detection of amyloid deposits using e.g. positron emission tomography (PET). [0056]
  • With alkyl is preferably meant a chain of 4 or less carbon atoms, e.g. methyl, ethyl, propyl or butyl. [0057]
  • With cykloalkyl is preferably meant a ring of 3, 4, 5 or 6 carbon atoms. [0058]
  • Aryl preferably means a phenyl group, which can be substituted, preferably by a methyl, ethyl, propyl or butyl group, an amino or a methoxy, ethoxy, propoxy or butoxy group. [0059]
  • In one embodiment of this second aspect of the invention, a compound is used, wherein all the amino acids are D-isomers. [0060]
  • In a particular embodiment of this aspect of the invention, Y′ is Lys. A particular embodiment is when Z′ is Phe, resulting in a compound of the following formula: [0061]
  • R1-A′—NH—CH[(CH2)4—NH2]—CO—Leu-X′—NH—CH[—CH2—Ph]—CO—B′R2.
  • In an alternative embodiment, a compound is used, wherein Y′ is Phe while Z′ is any non-acidic amino acid. [0062]
  • In a preferred embodiment of this aspect of the invention, a compound is used, wherein X′ is Val-Val. [0063]
  • In one embodiment of the use according to the invention, R[0064] 1 is acetyl. Alternatively, R1 and/or R2 are H.
  • Yet another aspect of the present invention is a compound according to the invention for use as a medicament. [0065]
  • Also claimed is the use of a compound, preferably of the formula (I) or (II), which is able to bind to the KLVFF-sequence in amyloid β peptide and which has the ability to inhibit polymerization of amyloid β peptide, for the manufacture of a medicament for the treatment or prevention of amyloidosis, especially in the treatment or prevention of Alzheimer's disease associated with amyloidosis, for the treatment or prevention of demens in patients with Down's syndrome, for the treatment or prevention of Hereditary cerebral hemorrhage with amyloidosis (Dutch type) or for the prevention of fibril formation of human amyloid protein. [0066]
  • Further, a last aspect of the present invention is a composition comprising a compound according to formula II and optionally a ligand capable of binding or interacting with the compound according to formula II and a carrier. [0067]
  • Said composition can e.g. be adapted for injection in a liquid carrier or for oral administration in a tablet or capsule. [0068]
  • Carriers are known for persons skilled in the art. For clarification the following definitions are given: [0069]
  • K is lysine (Lys), L is leucine (Leu), V is valine (Val), F is phenylalanine (Phe), A is alanine (Ala) and E is glutamic acid (Glu). As used herein, “any group giving the compound according to formula (I) the ability to bind to the KLVFF-sequence in the amyloid β peptide” means that this group gives the compound a structure, which can fulfil the requirements given in [0070] claim 1.
  • The hydrocarbon ring or heterocyclic ring has preferably 4-6 atoms, preferably C, N and S.[0071]
    • DESCRIPTION OF THE FIGURES
  • FIGS. 1 A and B. Aβ-amyloid polymerization. [0072]
  • FIG. 2A. Ten-mers corresponding to consecutive sequences of Aβ-1-40. Radioactivity bound to the filter was detected by autoradiography and quantified by densitometry. [0073]
  • FIG. 2B. EVHHQKLVFF and N and C-terminal truncated fragments were synthesized and analyzed for affinity to [0074] 125I-labelled Aβ-1-40.
  • FIG. 2C. Each amino acid residue in KLVFF was systematically replaced with Ala and analyzed for affinity to [0075] 125I-labelled Aβ-1-40.
  • FIG. 2D. Sensorgram from surface plasmon resonance spectroscopy (BIAcore 2000). [0076]
  • FIGS. 3 A and B. Content of non-aggregated peptide in the supernatants from incubations of wild-type and Ala-substituted Aβ-1-28 as analyzed by HPLC.[0077]
    • EXPERIMENTAL EXAMPLE 1
  • a) Ten-mers corresponding to consecutive sequences of Aβ-1-40 were synthesized on a filter matrix using the SPOT-technique (the peptides were synthesized essentially as described by Frank [R. Frank, [0078] Tetrahedron 42, 9217-9232 (1992)]. Briefly, a spacer corresponding to 2 molecules of β-alanine was coupled to cellulose membranes (Whatman lChr). The peptides were synthesized on these derivatized membranes using Fmoc protected and pentafluorophenyl-activated amino acids (AMS Biotechnology) dissolved in N-methylpyrrolidone. Coupling efficiency was monitored using bromphenol blue.). We synthesized the thirty-one possible 10-mers of the Aβ-1-40. Peptide no. 1 corresponds to amino acids 1-10, peptide no. 2 to amino acids 2-11 etc. The filter-bound peptides were incubated with radioactive Aβ-1-40. Following washing of the filter in high-salt buffer, bound radioactivity was estimated by autoradiography and densitometry. Following blocking with 0.05% Tween-20 in Tris-buffered saline (TBS), the filter was incubated in the presence of 20 μM 125I-labelled Aβ-1-40 at 20° C. for 12 h in TBS, pH 7.3, supplemented with 1% bovine serum albumin. The filter was then washed repeatedly in the same buffer containing 0.5 M NaCl and dried. Radioactivity bound to the filter was visualized by autoradiography and quantitated using a densitometer.
  • b) Peptide no. 11 (EVHHQKLVFF) and indicated N- and C-terminal truncated fragments were synthesized using the same technique as described above and analyzed for affinity to [0079] 125I-labelled Aβ-1-40.
  • c) Sensorgram from BIAcore 2000. Aβ-1-40, at three different concentrations in running buffer, pH 7.4. Aβ-1-40 was injected during 10 minutes over a sensor-chip derivatized with the peptide KLVFF-βA-βA-C. [0080]
  • d) Each amino acid residue in KLVFF was systematically replaced with A and analyzed for affinity to [0081] 125I-labelled Aβ-1-40. Non-specific interactions have been compensated for by subtracting the signal from a surface derivatized with C alone.
  • Results [0082]
  • a) The measured binding should be interpreted as semiquantative, since the coupling efficiency and therefore the amount of peptide per spot may vary. A region located in the central part of Aβ (Aβ-9-18 to Aβ-13-22) displayed prominent binding of radioactive Aβ-1-40. Another binding region was the hydrophobic C-terminus of the molecule (D. Burdick, et al, [0083] J. Biol. Chem. 267, 546-554 (1992)) but binding here was considerably weaker (FIG. 2A).
  • b) Being located in the centre of the binding region, peptide no. 11 (corresponding to Aβ-11-20) was selected for further studies. This peptide, as well as N- and C-terminal fragments thereof, were synthesized using the same technique as described previously. The shortest peptide still displaying high Aβ binding capacity had the sequence KLVFF, corresponding to amino acids 16-20 of Aβ (FIG. 2B). By systematically substituting the amino acid residues in the KLVFF sequence with alanine, we found that the first, second and fifth residues (i.e. KLXXF) were critical for binding (FIG. 2C). [0084]
  • c) The interaction between soluble Aβ-1-40 and immobilized KLVFF was monitored in real-time (FIG. 2D) using surface plasmon resonance spectroscopy (BIAcore, Pharmacia) (BIAcore 2000 (Pharmacia Biosensor AB, Sweden) was used for real-time studies based on surface plasmon resonance spectroscopy. The peptide was immobilized using thiol coupling. The running buffer consisted of 10 mM HEPES, 0.15 M NaCl, 3.4 mM EDTA and 0.05% surfactant P20 as described. [U. Jansson, M. Malmqvist, [0085] Adv. Biosens. 2, 291-336 (1992)]). The binding was not saturable, indicating that Aβ-1-40 bound to immobilized KLVFF could interact with other Aβ-1-40 molecules in a polymerization reaction.
  • d) AA served as linker between the active peptide and the chip (upper trace) and cysteine alone, indicating non-specific binding, (C) as control (lower trace). Arrows indicate start and stop of injection (FIG. 2D). [0086]
    • EXAMPLE 2
  • To investigate if the KLXXF motif was required for Aβ polymerization, we synthesized Aβ-1-28, a well-studied Aβ fragment that readily forms amyloid fibrils (D. A. Kirschner, et al., [0087] Proc. Natl. Acad. Sci. USA 84, 6953-6957 (1987); C. J. Barrow, M. G. Zagorski, Science 253, 179-82 (1991); C. Nordstedt, et al., J. Biol. Chem. 269, 30773-30776 (1994)) and mutated Aβ-1-28 where the KLVFF sequence was substituted with AAVFA (Aβ-1-28AAVFA).
  • Aβ-1-28 (FIG. 3 A) and Aβ-1-28[0088] AAVFA (FIG. 3 B) were incubated at 200 μM in TBS for 24 h at 37° C. in a shaking water bath. After incubation, the tubes were centrifuged at 20,000 g for 20 min and the content of non-aggregated peptide in the supernatants (FIG. 3 A, B) was analyzed using an established C4 RPLC system (12) whereas the aggregated peptides in the pellets were analyzed by electron microscopy after adsorption to formvar-coated grids and negative staining with 2% uranyl acetate in water.
  • Results [0089]
  • Following incubation at a concentration of 200 μM for 24 h at 37° C., Aβ-1-28 aggregated (FIG. 3A) and formed large fibril bundles, whereas Aβ-1-28[0090] AAVFA almost completely failed to aggregate (FIG. 3B) and only formed a few dispersed fibrils.
    • EXAMPLE 3
  • Aβ-1-40 was incubated at 100 μM in TBS for 48 h at 37° C. in a shaking water bath, either alone or together with 100 μM AcKLVFFNH[0091] 2. The polymerized material was adsorbed to formvar-coated grids and negatively stained with 2% uranyl acetate in water.
  • Results [0092]
  • Incubation of synthetic Aβ-1-40 at 100 μM for 48 h at 37° C. in a physiological buffer led to polymerization and formation of amyloid fibrils arranged in parallel in densely packed bundles, as previously shown (C. Nordstedt, et al., [0093] J. Biol. Chem. 269, 30773-30776 (1994)). When Aβ-1-40 was coincubated with AcQKLVFFNH2 at equimolar concentrations, this type of fibrils did not form. Instead, only a few occasional fibrils embedded in a diffuse background of small rod-like aggregates, similar to those formed by AcQKLVFFNH2 itself, could be detected.
    • EXAMPLE 4
  • The peptides were synthesized essentially as described by Frank (Frank R, 1992, Tetrahedron 42:9217-9232). Briefly, a spacer corresponding to 2 molecules of β-alanine was coupled to cellulose membranes (Whatman XX). The peptides were synthesized on these derivatized membranes using Fmoc protected and pentafluorophenyl-activated amino acids (AMS biotechnology) dissolved in N-methylpyrrolidone. Coupling efficiency was monitored using bromphenol blue. [0094]
  • Results [0095]
  • The KLXXF motif in the Aβ molecule is not only critical for polymerization and fibril formation. During non-amyloidogenic processing of APP, the molecule is cleaved between amino acid residues K[0096] 16 and L17 (F. S. Esch, et al., Science 248, 1122-1124 (1990)), leading to the formation of a fragment of Aβ termed p3 and corresponding to Aβ-17-40 or Aβ-17-42 (C. H{dot over (a)}ass, A. Y. Hung, M. G. Schlossmacher, D. B. Teplow, D. J. Selkoe, J. Biol. Chem. 268, 3021-3024 (1993)). Through this metabolic pathway the present binding sequence is disrupted. This may explain why p3 is not capable of forming amyloid in vitro or in vivo (J. Näslund, et al., Proc. Natl. Acad. Sci. USA 91, 8378-8382 (1994); J. Näslund, et al., Biochem. Biophys. Res. Commun. 204, 780-787 (1994)). The KLXXF motif is highly sequence specific. The most apparent example of this is the finding that substitution of a single amino acid leads to virtually complete loss of Aβ binding capacity.
    • EXAMPLE 5
  • In an additional series of experiments, it was demonstrated that KLVFF binds stereo specifically to the homologous sequence in Aβ (i.e. . Aβ-16-20). By screening combinatorial pentapeptide libraries exclusively composed of D-amino acids (lowercase) with labelled KLVFF, several ligands with a motif containing phenylalanine (f) in the second and leucine (l) in the third position were identified (e.g. lflrr). By using a short peptide in the screening, known to bind to a region in Aβ critical for its polymerization (i.e. KLVFF), the risk of identifying D-pentapeptides that interact with nonrelevant regions in Aβ (N- or C-terminal to Aβ-16-20) was eliminated. Like KLVFF, the D-amino acid ligands were found not only to bind to Aβ but also to inhibit amyloid fibril formation. Since peptides built up of D-amino acids are resistant to proteolytic degradation, these ligands way be beneficial for inhibition of amyloidogenesis in vivo. The results further indicate that KLVFF will be useful in the identification of small organic molecules (e.g. by screening of substance libraries) with the ability to bind to Aβ in this relevant region and inhibit amyloid fibril formation (candidate drugs for the treatment of Alzheimer disease and other related amyloidoses). [0097]
  • Discussion and Conclusion [0098]
  • Previous studies of putative inhibitors of amyloid fibril formation showed that cyclodextrins (P. Camilleri, N. J. Haskind, D. R. Howlett, [0099] FEBS Lett. 341, 256-258 (1994)) and Congo red (A. Lorenzo, H. Yankner, Proc. Natl. Acad. Sci. USA 91, 12243-12247 (1994)) may have such properties. The usefulness of these molecules as lead or model substances in development of anti-Alzheimer amyloid drugs is, however, compromised by their relative lack of specificity. Cyclodextrins have primarily been used to increase the solubility of a wide range of lipophilic drugs and it is unlikely that they would display any specificity for Aβ in vivo. Congo red, which is used in histochemistry to detect amyloid, binds to a wide array of non-Aβ amyloids as well as to other proteins with a high content of β-pleated sheet structures (W. G. Turnell, J. T. Finch, J. Mol. Biol. 227, 1205-1223 (1992)).
  • Due to the extreme insolubility of amyloid, strong chaotropic agents or potent organic solvents are required for its dissolution (C. L. Masters, et al., [0100] Proc. Natl. Acad. Sci. USA 82, 4245-4249 (1985)), the concept of dissolving amyloid deposits in situ under physiological conditions may seem futile. However, the bulk of the individual molecules in amyloid are probably not joined by covalent bonds and the deposition of Aβ into amyloid is, at least at some stages, a dynamic and reversible process (J. E. Maggio, et al., ibid., 89, 5462-5466 (1992)). Hence, a molecule capable of binding to a site in the Aβ molecule that is critical for fibril formation with an affinity higher than native Aβ should have reasonable chances to inhibit amyloid growth and maybe also specifically dissolve amyloid fibrils.
  • In conclusion, we have identified an Aβ sequence, KLVFF, which is required for amyloid fibril formation. The KLVFF peptide may serve as a model substance for the synthesis of non-peptide Aβ-ligands that interfere with the polymerization of Aβ molecules. [0101]
  • Previous studies suggested that amino acid residues within or close to Aβ-16-20 are important for the adoption of the correct β-pleated sheet structure of Aβ (18) and the proteolytic processing of its precursor (14). [0102]
  • We have now shown that this region harbors at least one binding sequence required for the polymerization of Aβ into amyloid fibrils. It was also demonstrated that short peptides incorporating Aβ-16-20 can function as ligands that bind to Aβ and inhibit the formation of amyloid fibrils. Since these peptide ligands are relatively small, they are amenable for identification of other organic molecules with similar functional properties. Non-peptide homologues of KLVFF should be useful as pharmacological drugs for the treatment of Alzheimer's disease in the future. [0103]
  • 1 44 1 5 PRT Amyloidosis 1 Lys Leu Val Phe Phe 1 5 2 10 PRT Amyloidosis 2 Glu Val His His Gln Lys Leu Val Phe Phe 1 5 10 3 5 PRT Amyloidosis PEPTIDE (3)..(4) Amino acids 3 and 4 are Xaa wherein Xaa = any amino acid. 3 Lys Leu Xaa Xaa Phe 1 5 4 5 PRT Amyloidosis 4 Ala Ala Val Phe Ala 1 5 5 6 PRT Amyloidosis 5 Gln Lys Leu Val Phe Phe 1 5 6 9 PRT Amyloidosis 6 Val His His Gln Lys Leu Val Phe Phe 1 5 7 9 PRT Amyloidosis 7 Glu Val His His Gln Lys Leu Val Phe 1 5 8 8 PRT Amyloidosis 8 His His Gln Lys Leu Val Phe Phe 1 5 9 8 PRT Amyloidosis 9 Val His His Gln Lys Leu Val Phe 1 5 10 8 PRT Amyloidosis 10 Glu Val His His Gln Lys Leu Val 1 5 11 7 PRT Amyloidosis 11 His Gln Lys Leu Val Phe Phe 1 5 12 7 PRT Amyloidosis 12 His His Gln Lys Leu Val Phe 1 5 13 7 PRT Amyloidosis 13 Val His His Gln Lys Leu Val 1 5 14 7 PRT Amyloidosis 14 Glu Val His His Gln Lys Leu 1 5 15 6 PRT Amyloidosis 15 His Gln Lys Leu Val Phe 1 5 16 6 PRT Amyloidosis 16 His His Gln Lys Leu Val 1 5 17 6 PRT Amyloidosis 17 Val His His Gln Lys Leu 1 5 18 6 PRT Amyloidosis 18 Glu Val His His Gln Lys 1 5 19 5 PRT Amyloidosis 19 Gln Lys Leu Val Phe 1 5 20 5 PRT Amyloidosis 20 His Gln Lys Leu Val 1 5 21 5 PRT Amyloidosis 21 His His Gln Lys Leu 1 5 22 5 PRT Amyloidosis 22 Val His His Gln Lys 1 5 23 5 PRT Amyloidosis 23 Glu Val His His Gln 1 5 24 4 PRT Amyloidosis 24 Leu Val Phe Phe 1 25 4 PRT Amyloidosis 25 Lys Leu Val Phe 1 26 4 PRT Amyloidosis 26 Gln Lys Leu Val 1 27 4 PRT Amyloidosis 27 His Gln Lys Leu 1 28 4 PRT Amyloidosis 28 His His Gln Lys 1 29 4 PRT Amyloidosis 29 Val His His Gln 1 30 4 PRT Amyloidosis 30 Glu Val His His 1 31 3 PRT Amyloidosis 31 Val Phe Phe 1 32 3 PRT Amyloidosis 32 Leu Val Phe 1 33 3 PRT Amyloidosis 33 Lys Leu Val 1 34 3 PRT Amyloidosis 34 Gln Lys Leu 1 35 3 PRT Amyloidosis 35 His Gln Lys 1 36 3 PRT Amyloidosis 36 His His Gln 1 37 3 PRT Amyloidosis 37 Val His His 1 38 3 PRT Amyloidosis 38 Glu Val His 1 39 5 PRT Amyloidosis 39 Ala Leu Val Phe Phe 1 5 40 5 PRT Amyloidosis 40 Lys Ala Val Phe Phe 1 5 41 5 PRT Amyloidosis 41 Lys Leu Ala Phe Phe 1 5 42 5 PRT Amyloidosis 42 Lys Leu Val Ala Phe 1 5 43 5 PRT Amyloidosis 43 Lys Leu Val Phe Ala 1 5 44 8 PRT Amyloidosis 44 Lys Leu Val Phe Phe Ala Ala Cys 1 5

Claims (26)

We claim:
1. A compound having the formula
R1-A′-Y′-Leu-X′-Z′-B′-R2   (I)
in which
X′ means any group or amino acid imparting to the compound of formula (I) the ability to bind to the KLVFF-sequence in amyloid β peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline;
Y′ means any amino acid;
Z′ means any non-acidic amino acid;
A′ means a direct bond or an α-amino acid bonded at the carboxyl terminal of the α-carboxygroup or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α-carboxy group;
B′ means a direct bond or an α-amino acid bonded at the α-nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α-nitrogen of the N-terminal α-amino acid; R1 is H or —CO—R3 bonded at the α-amino group of A′; R2 is H, —OR4 or NR5R6, all bound to the α-carboxyl group of the a-carboxyterminal of B′;
R3 is a straight or branched carbon chain of 1-4 carbon atoms;
R4 is a straight or branched carbon chain of 1-4 carbon atoms;
R5 and R6 independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are —(CH2)n—, where n is 4-5;
R1 and R2 together can form a hydrocarbon ring or heterocyclic ring; and
all the α-amino acids can be either D- or L-isomers; with the proviso that (I) is not Lys-Leu-Val-Phe-Phe, which exhibits an ability to inhibit polymerization of amyloid β peptide.
2. A compound according to claim 1, wherein all the amino acids are D-isomers.
3. A compound according to claim 1, wherein Y′ is Lys.
4. A compound according to claim 2, wherein Y′ is Lys.
5. A compound according to claim 3, wherein Y′ is Lys and Z′ is Phe.
6. A compound according to claim 1, wherein Y′ is Phe.
7. A compound according to claim 2, wherein Y′ is Phe.
8. A compound according to claim 1, wherein X′ is Val-Val.
9. A compound according to claim 1, wherein R1 is acetyl.
10. A compound according to claim 1, wherein R1 is H and/or R2 is H.
11. Use of a compound of formula
R1-A′-Y′-Leu-X′-Z′-B′-R2   (II)
in which
X′ means any group or amino acid imparting to the compound of formula (II) the ability to bind to the KLVFF-sequence in the amyloid β peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline;
Y′ means any amino acid;
Z′ means any non-acidic amino acid;
A′ means a direct bond or an α-amino acid bonded at the carboxyl terminal of the α-amino acid bonded at the carboxyl terminal of the α-carboxygroup or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α-carboxy group;
B′ means a direct bond or an α-amino acid bonded at the α-nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α-nitrogen of the N-terminal α-amino acid;
R1 is H or —CO—R3 bonded at the α-amino group of A′;
R2 is H, —OR4 or NR3R6, all bound to the α-carboxyl group of the α-carboxyterminal of B′;
R3 is a straight or branched carbon chain of 1-4 carbon atoms;
R4 is a straight or branched carbon chain of 1-4 carbon atoms;
R5 and R6 independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are —(CH2)n—, where n is 4-5;
R1 and R2 together can form a hydrocarbon ring or heterocyclic ring;
all the α-amino acids can be either D- or L-isomers;
for inhibition of polymerization of amyloid β peptide-ligands for inhibition of polymerization of amyloid β peptide, as a tool for the identification of other organic compounds with similar functional properties or as a ligand in PET (positron emission tomography).
12. Use according to claim 11, wherein all the amino acids of the compound are D-isomers.
13. Use according to claim 9, wherein 20 Y′ is Lys.
14. Use according to claim 13, wherein Y′ is Lys and Z′ is Phe.
15. Use according to claim 11, wherein Y′ is Phe.
16. Use according to claim 11, wherein X′ is Val-Val.
17. Use according to claim 11, wherein R1 is acetyl.
18. Use according to claim 11, wherein R1 is H and/or R2 is H.
19. A compound according to claim 1 for use as a medicament.
20. Use of a compound according to claim 1 for the manufacture of a medicament for the treatment of prevention of amyloidosis.
21. Use of a compound according to claim 1 for the manufacture of a medicament for the treatment of prevention of Alzheimer disease associated with amyloidosis.
22. Use of a compound according to claim 1 for the manufacture of a medicament for the treatment or prevention of demens in patients with Down's syndrome.
23. Use of a compound according to claim 1 for the manufacture of a medicament for the treatment or prevention of Hereditary cerebral hemorrhage with amyloidosis (Dutch type).
24. Use of a compound according to claim 1 for the manufacture of a medicament for the prevention of fibril formation of human amyloid protein.
25. A composition comprising a compound according to claim 1 and optionally a ligand capable of binding or interacting with the compound according to formula I and a carrier.
26. A composition according to claim 25, which is adapted for injection or oral administration.
US09/850,061 1995-12-12 2001-05-08 Peptide binding the KLVFF-sequence of amyloid-beta Abandoned US20020094957A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/850,061 US20020094957A1 (en) 1995-12-12 2001-05-08 Peptide binding the KLVFF-sequence of amyloid-beta
US10/721,774 US7288523B2 (en) 1995-12-12 2003-11-26 Peptide binding the KLVFF-sequence of amyloid-β

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE9504467-3 1995-12-12
SE9504467A SE9504467D0 (en) 1995-12-12 1995-12-12 Peptide
US938695P 1995-12-29 1995-12-29
PCT/SE1996/001621 WO1997021728A1 (en) 1995-12-12 1996-12-09 PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US09/095,106 US6331440B1 (en) 1995-12-12 1998-06-10 Peptide binding the KLVFF-sequence of amyloid-β
US09/850,061 US20020094957A1 (en) 1995-12-12 2001-05-08 Peptide binding the KLVFF-sequence of amyloid-beta

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/SE1996/001621 Division WO1997021728A1 (en) 1995-12-12 1996-12-09 PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US09095106 Division 1996-12-09
US09/095,106 Division US6331440B1 (en) 1995-12-12 1998-06-10 Peptide binding the KLVFF-sequence of amyloid-β

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/721,774 Continuation US7288523B2 (en) 1995-12-12 2003-11-26 Peptide binding the KLVFF-sequence of amyloid-β

Publications (1)

Publication Number Publication Date
US20020094957A1 true US20020094957A1 (en) 2002-07-18

Family

ID=26662451

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/095,106 Expired - Fee Related US6331440B1 (en) 1995-12-12 1998-06-10 Peptide binding the KLVFF-sequence of amyloid-β
US09/850,061 Abandoned US20020094957A1 (en) 1995-12-12 2001-05-08 Peptide binding the KLVFF-sequence of amyloid-beta
US10/721,774 Expired - Fee Related US7288523B2 (en) 1995-12-12 2003-11-26 Peptide binding the KLVFF-sequence of amyloid-β

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/095,106 Expired - Fee Related US6331440B1 (en) 1995-12-12 1998-06-10 Peptide binding the KLVFF-sequence of amyloid-β

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/721,774 Expired - Fee Related US7288523B2 (en) 1995-12-12 2003-11-26 Peptide binding the KLVFF-sequence of amyloid-β

Country Status (4)

Country Link
US (3) US6331440B1 (en)
EP (1) EP0866805A1 (en)
AU (1) AU1072897A (en)
WO (1) WO1997021728A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745349B2 (en) 2012-12-27 2017-08-29 Japan Science And Technology Agency Cyclic peptide and pharmaceutical product containing same

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
AU1072897A (en) 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
DK0929574T3 (en) * 1996-08-27 2005-10-31 Praecis Pharm Inc Modulators of beta-amyloid peptide aggregation which include D-amino acids
DK0915088T3 (en) 1997-10-31 2003-01-27 Hoffmann La Roche D-proline derivatives
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EP1161449B1 (en) * 1999-03-04 2007-07-04 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
EP1870419A3 (en) * 1999-03-04 2008-01-02 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
ATE384077T1 (en) * 1999-05-05 2008-02-15 Neurochem Int Ltd STEREOSELECTIVE ANTIFIBRILOGENIC PEPTIDES
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
GB9917724D0 (en) 1999-07-28 1999-09-29 Medical Res Council Peptides
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
US20070135337A2 (en) * 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US20070020662A1 (en) * 2000-01-07 2007-01-25 Transform Pharmaceuticals, Inc. Computerized control of high-throughput experimental processing and digital analysis of comparative samples for a compound of interest
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
US20040252299A9 (en) * 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US20070021929A1 (en) * 2000-01-07 2007-01-25 Transform Pharmaceuticals, Inc. Computing methods for control of high-throughput experimental processing, digital analysis, and re-arraying comparative samples in computer-designed arrays
CN1312264A (en) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 Human amyloid glycoprotein 11 as one new polypeptide and polynucleotides encoding this polypeptide
AU2002217953A1 (en) * 2000-11-28 2002-06-11 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20020132758A1 (en) * 2001-01-18 2002-09-19 Shell John W. Method for identifying compounds to treat medical pathologies associated with molecular crystallization
CA2441562C (en) * 2001-03-28 2013-05-14 Helix Biomedix, Inc. Short bioactive peptides and methods for their use
US20050209157A1 (en) * 2001-03-28 2005-09-22 Owen Donald R Short bioactive peptides and methods for their use
US6875744B2 (en) * 2001-03-28 2005-04-05 Helix Biomedix, Inc. Short bioactive peptides
AUPR976401A0 (en) * 2001-12-27 2002-01-31 Alzhyme Pty Ltd Agents for the treatment of alzheimer's disease and screening methods for the same
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10230141B4 (en) * 2002-07-04 2004-07-15 Priontype Gmbh Method and kit for the enrichment and detection of modified prion proteins (PrPSc)
US8871447B2 (en) * 2002-09-12 2014-10-28 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
MXPA05006940A (en) * 2002-12-24 2006-02-22 Neurochem Int Ltd Therapeutic formulations for the treatment of beta-amyloid related diseases.
WO2004100998A2 (en) 2003-05-07 2004-11-25 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20060069010A1 (en) * 2003-10-17 2006-03-30 Senicure Llc Detoxification depot for Alzheimer's disease
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
ES2378242T3 (en) * 2005-02-09 2012-04-10 Helix Biomedix, Inc. Antimicrobial hexapeptides
ES2259270B1 (en) * 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas IN VITRO DIAGNOSTIC METHOD OF ALZHEIMER'S DISEASE BY A MONOCLONAL ANTIBODY.
US20100130416A1 (en) * 2005-11-10 2010-05-27 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
KR20080095836A (en) * 2005-11-10 2008-10-29 로스캄프 리서치 엘엘씨 Modulation of Angiogenesis by A-beta Peptide Fragments
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PL2238166T3 (en) 2007-10-05 2014-07-31 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
RU2607368C2 (en) 2010-07-30 2017-01-10 Ац Иммуне С.А. Safe and functional humanized antibodies
WO2013021353A1 (en) * 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004498A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
EP3374381A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia EPITAOPES IN THE CENTRAL REGION OF BETA-AMYLOID AND RELATED CONFORMATIONAL ANTIBODIES
CN116333108A (en) 2016-07-18 2023-06-27 英属哥伦比亚大学 Antibody to amyloid beta
US20180125920A1 (en) * 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
WO2019134039A1 (en) * 2018-01-04 2019-07-11 Septa Therapeutics, Inc. Septapeptides associated with neurodegeneracy
CN110780076B (en) * 2019-10-24 2023-02-17 南开大学 Preparation method and application of sensitive beta-amyloid protein nano fluorescent probe

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470951A (en) * 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
US5578451A (en) * 1993-02-18 1996-11-26 The General Hospital Corporation Methods and systems for screening potential alzheimer's disease therapeutics
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4116768A (en) 1975-04-29 1978-09-26 (Zaidanhojin) Sagami Chemical Research Center Process for producing a peptide
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5002872A (en) 1989-05-10 1991-03-26 W. R. Grace & Co.-Conn. Enzyme mediated coupling reactions
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US6261569B1 (en) 1992-08-27 2001-07-17 Deakin Research Limited Retro-, inverso- and retro-inverso synthetic peptide analogues
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
WO1995005393A2 (en) 1993-08-18 1995-02-23 Morphosys Gesellschaft Für Proteinoptimierung Mbh Lipopolysaccharide-binding and neutralizing peptides
DK96493D0 (en) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps PROCEDURE FOR INDUCING ANTIBODY RESPONSE TO SELF-PROTEINS AND AUTOVACCINE PROCESSED BY THE PROCEDURE
AU707083B2 (en) 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
US5652334A (en) 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
AUPM411994A0 (en) 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
BR9507742A (en) 1994-05-20 1997-10-07 Novavax Inc Antimicrobial oil-in-water emulsions
US6294353B1 (en) 1994-10-20 2001-09-25 Morphosys Ag Targeted hetero-association of recombinant proteins to multi-functional complexes
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
WO1996034887A2 (en) * 1995-05-05 1996-11-07 Imperial College Of Science, Technology & Medicine Antisense peptides
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
AU1072897A (en) 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
JP2000505306A (en) 1996-02-26 2000-05-09 モルフォシス・アクチェンゲゼルシャフト Novel method for identifying nucleic acid sequences encoding two or more interacting (poly) peptides
US6436903B1 (en) 1996-05-22 2002-08-20 Stanford University (Board Of Trustees Of The Leland Standford Junior University) Immunomodulating compounds comprising d-isomers of amino acids
ATE253593T1 (en) 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr IMMUNOGLOBULIN SUPERFAMILY DOMAINS AND FRAGMENTS WITH INCREASED SOLUBILITY
DK0929574T3 (en) 1996-08-27 2005-10-31 Praecis Pharm Inc Modulators of beta-amyloid peptide aggregation which include D-amino acids
US6022859A (en) 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
FR2761058B1 (en) * 1997-03-19 1999-05-21 Goemar Lab Sa COMPOSITION AND METHOD FOR STIMULATING THE GERMINATION OF POLLEN GRAINS
JP2002501721A (en) 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト Novel method and phage for identifying nucleic acid sequences encoding members of multimeric (poly) peptide complexes
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
ES2253839T3 (en) 1997-12-03 2006-06-01 Neuralab, Ltd. SUPPRESSION OF CHANGES RELATED TO AMILOID BETA IN THE DISEASE OF ALZHEIMER.
NO314086B1 (en) 1998-05-08 2003-01-27 Gemvax As Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for
EP1080110A2 (en) 1998-05-19 2001-03-07 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
IL139095A0 (en) 1998-05-21 2001-11-25 Univ Tennessee Res Corp Methods for amyloid removal using anti-amyloid antibodies
CZ20011049A3 (en) 1998-10-05 2002-08-14 Pharmexa A/S Immunogenic composition and method for selecting immunogenic analog
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
WO2000043039A1 (en) 1999-01-22 2000-07-27 Matthew John During Vaccine-mediated treatment of neurological disorders
EP1161449B1 (en) 1999-03-04 2007-07-04 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
ATE384077T1 (en) 1999-05-05 2008-02-15 Neurochem Int Ltd STEREOSELECTIVE ANTIFIBRILOGENIC PEPTIDES
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
BR0016022A (en) 1999-11-29 2002-08-06 Neurochem Inc Vaccine for the prevention and treatment of alzheimer's disease and amyloid-related diseases
US20070135337A2 (en) 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
AU8431301A (en) 1999-12-23 2001-11-20 Neurochem (International) Limited Compounds and methods for modulating cerebral amyloid angiopathy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578451A (en) * 1993-02-18 1996-11-26 The General Hospital Corporation Methods and systems for screening potential alzheimer's disease therapeutics
US5470951A (en) * 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745349B2 (en) 2012-12-27 2017-08-29 Japan Science And Technology Agency Cyclic peptide and pharmaceutical product containing same

Also Published As

Publication number Publication date
AU1072897A (en) 1997-07-03
WO1997021728A1 (en) 1997-06-19
EP0866805A1 (en) 1998-09-30
US6331440B1 (en) 2001-12-18
US7288523B2 (en) 2007-10-30
US20040157781A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
US6331440B1 (en) Peptide binding the KLVFF-sequence of amyloid-β
Tjernberg et al. Controlling amyloid β-peptide fibril formation with protease-stable ligands
RU2260599C2 (en) MODULATING AGENT FOR AGGREGATION OF β-AMYLOID FOR AGGREGATION INHIBITION OF NATURAL β-AMYLOID OR FOR TREATMENT OF SUBJECT WITH DISORDER ASSOCIATED WITH β-AMYLOIDOSIS, PHARMACEUTICAL COMPOSITION AND METHOD FOR DETECTION OF NATURAL β-AMYLOID PEPTIDE IN BIOLOGICAL SAMPLE
US6462171B1 (en) Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
EP0787146B1 (en) Compounds and methods for inhibiting beta-protein filament formation and neurotoxicity
US5985242A (en) Modulators of β-amyloid peptide aggregation comprising D-amino acids
JP2003530554A (en) Prion binding peptide ligands and methods of using the same
US5721106A (en) In Vitro method for screening β-amyloid deposition
US8613905B2 (en) Diagnostic agent
JP5947801B2 (en) Peptide compounds useful for inhibition of amyloid plaque formation
CA2262453A1 (en) Modulators of .beta.-amyloid peptide aggregation comprising d-amino acids
Liu et al. Study on the efficiency and interaction mechanism of a decapeptide inhibitor of β-amyloid aggregation
CN101415724A (en) Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
JP4454230B2 (en) β-secretase substrate and use thereof
Tillett et al. N-Amino peptide scanning reveals inhibitors of Aβ 42 aggregation
Chikugo et al. Optimization of the Linker Length in the Dimer Model of E22P-Aβ40 Tethered at Position 38
Lambeir Interaction of prolyl oligopeptidase with α-synuclein
DK1725579T3 (en) Peptides derived from human BPLP protein, polynucleotides encoding said peptides and antibodies directed to said peptides
Potempska et al. Interaction between the β-amyloid peptide precursor and histones
Fülöp Aggregation studies, design and synthesis of amyloid aggregation inhibitors for the treatment of Alzheimer's disease
Lívia Aggregation Studies, Design and Synthesis of Amyloid Aggregation Inhibitors for the Treatment of Alzheimer's Disease
EP2090664A1 (en) Neuroprotective peptides
WO2007129077A2 (en) Imaging agent
Vyas Stabilization of secondary structure of synthetic Alzheimer beta-amyloid protein analogs in the presence of aluminum (III) ions
AU1553902A (en) Modulators of beta-amyloid peptide aggregation comprising D-amino acids

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NEUROCHEM (INTERNATIONAL) LIMITED, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KAROLINSKA INNOVATIONS AB;REEL/FRAME:016871/0367

Effective date: 20040830